Ezetimibe + RosuvastatinThird Party Manufacturing in India

This fixed-dose combination brings together two complementary lipid-lowering mechanisms. Ezetimibe selectively inhibits cholesterol absorption at the intestinal brush border by blocking the NPC1L1 protein, reducing dietary and biliary cholesterol uptake into enterocytes. Rosuvastatin works by competitively inhibiting HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis. By inhibiting this enzyme, rosuvastatin reduces intracellular cholesterol levels in the liver, leading to upregulation of LDL receptors on hepatocyte surfaces. These receptors then clear more LDL cholesterol from the bloodstream.

The dual mechanism is synergistic. Ezetimibe reduces the amount of cholesterol entering the body through the intestine, while rosuvastatin reduces the amount of cholesterol produced by the liver. Together, they achieve greater LDL-C reductions than either agent used alone at the same doses. This combination is particularly effective for patients with severe hyperlipidemia who require aggressive lipid lowering to reach target levels. The combination also reduces triglycerides and modestly increases HDL cholesterol. Both drugs have complementary pharmacokinetics and can be co-administered once daily without significant drug interaction, making this combination highly convenient for long-term therapy.

Therapeutic Uses

This fixed-dose combination is indicated as adjunctive therapy to diet and exercise in patients with primary hyperlipidemia or mixed dyslipidemia who require aggressive LDL-C reduction beyond what a statin alone can provide.

• Primary Hyperlipidemia and Mixed Dyslipidemia: For patients who have not achieved their lipid goals on statin monotherapy at maximal tolerated doses.
• Heterozygous Familial Hypercholesterolemia: Used as initial therapy when intensive lipid management is needed from the start of treatment.
• Cardiovascular Risk Reduction: The combination is preferred for patients with established cardiovascular disease who require additional LDL-C lowering beyond statin therapy alone, as supported by cardiovascular outcomes trial evidence.

Why Manufacturers Choose Ezetimibe + Rosuvastatin

Ezetimibe-rosuvastatin tablets are among the most prescribed fixed-dose combinations in India for dyslipidemia management. Indian pharmaceutical manufacturers produce this combination in three commonly used strengths: 10mg+5mg, 10mg+10mg, and 10mg+20mg, allowing physicians to titrate therapy based on patient needs.

The combination is manufactured under strict WHO-GMP guidelines and is a high-volume export product, particularly to regulated markets in Asia, Africa, and Latin America. Its popularity among PCD pharma franchise companies makes it a sought-after product for third party manufacturing in India. The convenience of a single tablet combining two complementary mechanisms drives patient compliance and repeat demand.